EE372 Cost-Utility of Ribociclib As the First-Line Treatment in Postmenopausal Women with Hormone Receptor Positive and Human Epidermal Growth Factor Receptor-2 Negative Advanced/Metastatic Breast Cancer in Colombia
Abstract
Authors
Ó Gamboa M Díaz Ortega D Herrera D Barbosa E Montenegro